Chong Kun Dang Pharmaceutical Corp.

Symbol: 185750.KS




Market price today

  • 6.1553

    P/E Ratio

  • 0.0089

    PEG Ratio

  • 1.31T

    MRK Cap

  • 0.01%

    DIV Yield

Chong Kun Dang Pharmaceutical Corp. (185750-KS) Stock Price & Analysis

Shares Outstanding


Gross Profit Margin


Operating Profit Margin


Net Profit Margin


Return on Assets


Return on Equity


Return on Capital Employed


Company general description and statistics

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
CEO:Mr. Young-Joo Kim
Full-time employees:2291
Address:8, Chungjeong-ro

Chong Kun Dang pharmaceutical Corp. engages in the manufacturing, marketing, and selling of medicines in South Korea and internationally. It provides prescription drugs for anti-hypertension, anti-hyperlipidemia, and anti-diabetics; over-the-counter drugs, such as Penzal, Prefemine, and Modcol, as well as consumer health products, such as insecticides, hair dye, etc.; and healthcare supplements with preventive benefits. The company also exports its products. Chong Kun Dang pharmaceutical Corp. was founded in 1941 and is headquartered in Seoul, South Korea.

General Outlook

In simple terms, Chong Kun Dang Pharmaceutical Corp. has 12.703 M shares that people are buying and selling right now. When we look at how much money they make before expenses, they keep 0.396% as profit. This shows they're good at controlling costs and are financially stable. Their operating profit, which is money made from regular business activities, is 0.148%. This means they run their business efficiently. Lastly, after paying all their bills, they still have a profit of 0.127%. This tells us they're good at keeping money after all costs.

Return on Investments

The company's asset efficiency, represented by a robust 0.152% return, is a testament to Chong Kun Dang Pharmaceutical Corp.'s adeptness in optimizing resource deployment. Chong Kun Dang Pharmaceutical Corp.'s utilization of its assets to generate profits is strikingly evident through a noteworthy return on equity of 0.296%. Furthermore, the proficiency of Chong Kun Dang Pharmaceutical Corp. in capital utilization is underscored by a remarkable 0.277% return on capital employed.

Stock Prices

Chong Kun Dang Pharmaceutical Corp.'s stock prices have been subject to undulating patterns. The peak stock value during this interval surged to $114500, while its low point bottomed out at $110600. This variance in figures offers investors a lucid insight into the roller-coaster ride that is Chong Kun Dang Pharmaceutical Corp.'s stock market.

Liquidity Ratios

Analyzing 185750.KS liquidity ratios reveals its financial health of the firm. The current ratio of 185.07% gauges short-term asset coverage for liabilities. The quick ratio (132.27%) assesses immediate liquidity, while the cash ratio (42.94%) indicates cash reserves.

Current Ratio185.07%
Quick Ratio132.27%
Cash Ratio42.94%

Profitability Ratios

185750.KS profitability indicators offer a lens into its earnings landscape. A pretax profit margin of 14.47% underscores its earnings before tax deductions. The effective tax rate stands at 11.59%, revealing its tax efficiency. The net income per EBT, 87.96%, and the EBT per EBIT, 97.96%, provide insights into its earnings hierarchy. Lastly, with an EBIT per revenue ratio of 14.77%, we grasp its operational profitability.

Pretax Profit Margin14.47%
Effective Tax Rate11.59%
Net Income per EBT87.96%
EBT per EBIT97.96%
EBIT per Revenue14.77%

Operational Efficiency

Operational metrics shed light on its business agility. With an operating cycle of 1.85, it details the span from stock purchase to revenue. The 1 days it takes to settle debts showcases its creditor relations.

Days of Sales Outstanding132
Days of Inventory Outstanding95
Operating Cycle162.68
Days of Payables Outstanding67
Cash Conversion Cycle96
Receivables Turnover5.36
Payables Turnover5.48
Inventory Turnover3.86
Fixed Asset Turnover5.22
Asset Turnover1.19

Cash Flow Ratios

Peering into the cash flow metrics reveals liquidity and operational efficiency. The operating cash flow per share, 25002.57, and free cash flow per share, 19595.45, depict cash generation on a per-share basis. The cash per share value, 28688.62, showcases liquidity position. A payout ratio of 0.05 highlights the portion of earnings distributed as dividends. Lastly, the operating cash flow sales ratio, 0.19, offers insight into cash flow relative to sales.

Operating Cash Flow per Share25002.57
Free Cash Flow per Share19595.45
Cash per Share28688.62
Payout Ratio0.05
Operating Cash Flow Sales Ratio0.19
Free Cash Flow to Operating Cash Flow Ratio0.78
Cash Flow Coverage Ratio1.48
Short Term Coverage Ratio1.72
Capital Expenditure Coverage Ratio4.62
Dividend Paid and Capex Coverage Ratio3.96
Dividend Payout Ratio0.01

Debt and Leverage Ratios

Diving into debt and leverage metrics unveils the company's financial structure. The debt ratio, at 15.31%, highlights its total liabilities relative to assets. With a debt-equity ratio of 0.26, we discern the balance between debt and equity financing. The long-term debt to capitalization, 3.55%, and total debt to capitalization, 20.84%, ratios shed light on its capital structure. An interest coverage of 26.60 indicates its ability to manage interest expenses.

Debt Ratio15.31%
Debt Equity Ratio0.26
Long Term Debt to Capitalization3.55%
Total Debt to Capitalization20.84%
Interest Coverage26.60
Cash Flow to Debt Ratio1.48
Company Equity Multiplier1.72

Per Share Data

Speaking about the per share data offers a perceptive view of financial distribution. The revenue per share, 131214.98, provides a glimpse into top-line earnings distributed across each share. Net income per share, 16704.14, reflects the portion of profit attributed to each share. The book value per share, 64113.48, represents the net asset value distributed per share, while the tangible book value per share, 59980.19, excludes intangible assets.

Revenue Per Share131214.98
Net Income Per Share16704.14
Book Value Per Share64113.48
Tangible Book Value Per Share59980.19
Shareholders Equity Per Share64113.48
Interest Debt Per Share17609.38
Capex Per Share-5408.15

Growth Ratios

Delving into growth metrics provides a snapshot of financial expansion. The revenue growth rate, 12.17%, indicates top-line expansion, while the gross profit growth, 207.65%, reveals profitability trends. EBIT growth, 124.37%, and operating income growth, 124.37%, offer insights into operational profitability progression. The net income growth, 163.86%, showcases bottom-line expansion, and the EPS growth, 1997.24%, measures the growth in earnings per share.

Revenue Growth12.17%
Gross Profit Growth207.65%
EBIT Growth124.37%
Operating Income Growth124.37%
Net Income Growth163.86%
EPS Growth1997.24%
EPS Diluted Growth-100.00%
Weighted Average Shares Growth-100.00%
Weighted Average Shares Diluted Growth-100.00%
Dividends per Share Growth-100.00%
Operating Cash Flow Growth-100.00%
Free Cash Flow Growth-100.00%
10-Year Revenue Growth per Share-100.00%
5-Year Revenue Growth per Share-100.00%
3-Year Revenue Growth per Share-100.00%
10-Year Operating CF Growth per Share-100.00%
5-Year Operating CF Growth per Share-100.00%
3-Year Operating CF Growth per Share-100.00%
10-Year Net Income Growth per Share-100.00%
5-Year Net Income Growth per Share-100.00%
3-Year Net Income Growth per Share-100.00%
10-Year Shareholders Equity Growth per Share-100.00%
5-Year Shareholders Equity Growth per Share-100.00%
3-Year Shareholders Equity Growth per Share-100.00%
5-Year Dividend per Share Growth per Share-100.00%
3-Year Dividend per Share Growth per Share-100.00%
Receivables Growth-100.00%
Inventory Growth-100.00%
Asset Growth24.67%
Book Value per Share Growth-100.00%
Debt Growth-100.00%
R&D Expense Growth-100.00%
SGA Expenses Growth-100.00%

Other Metrics

Venturing into other key metrics unveils diverse facets of financial performance. The enterprise value, 1,637,524,774,584, captures the company's total value, considering both debt and equity. Income quality, 1.50, assesses the reliability of reported earnings. The sales, general, and administrative to revenue ratio, 0.01, gauges operational efficiency, while the research and development to revenue, 8.40%, highlights investment in innovation. The ratio of intangibles to total assets, 3.75%, indicates the value of non-physical assets, and capex to operating cash flow, -21.63%, measures reinvestment capability.

Enterprise Value1,637,524,774,584
Income Quality1.50
Sales General and Administrative to Revenue0.01
Research and Development to Revenue8.40%
Intangibles to Total Assets3.75%
Capex to Operating Cash Flow-21.63%
Capex to Revenue-4.12%
Capex to Depreciation-186.25%
Graham Number155230.82
Return on Tangible Assets15.74%
Graham Net Net11207.51
Working Capital435,106,014,051
Tangible Asset Value763,108,022,539
Net Current Asset Value359,778,594,032
Average Receivables299,387,614,086.5
Average Payables164,687,512,701
Average Inventory265,756,675,024
Days Sales Outstanding68
Days Payables Outstanding66
Days of Inventory On Hand94

Valuation Ratios

Exploring the valuation ratios offers insights into perceived market value. The price to book value ratio, 1.60, and the price to book ratio, 1.60, reflect the market's valuation relative to the company's book value. The price to sales ratio, 0.78, provides a perspective on valuation in relation to sales. Ratios like price to free cash flows, 5.24, and price to operating cash flows, 4.11, gauge market valuation against cash flow metrics.

Price Book Value Ratio1.60
Price to Book Ratio1.60
Price to Sales Ratio0.78
Price Cash Flow Ratio4.11
Price Earnings to Growth Ratio0.01
Enterprise Value Multiple2.84
Price Fair Value1.60
Price to Operating Cash Flow Ratio4.11
Price to Free Cash Flows Ratio5.24
Price to Tangible Book Ratio2.01
Enterprise Value to Sales0.98
Enterprise Value Over EBITDA5.77
EV to Operating Cash Flow5.15
Earnings Yield12.98%
Free Cash Flow Yield15.23%
Trusted project
“All information displayed on the site is verified. High quality project and financial performance”
Eugene Alexeev
NumFin Founder and investing enthusiast

Frequently Asked Question

How many company shares are outstanding in 2024?

There are stock number shares outstanding of Chong Kun Dang Pharmaceutical Corp. (185750.KS) on the KSC in 2024.

What is P/E ratio of enterprise in 2024?

The current P/E ratio of enterprise is 6.155 in 2024.

What is the ticker symbol of Chong Kun Dang Pharmaceutical Corp. stock?

The ticker symbol of Chong Kun Dang Pharmaceutical Corp. stock is 185750.KS.

What is company IPO date?

IPO date of Chong Kun Dang Pharmaceutical Corp. is 2013-12-06.

What is company current share price?

Current share price is 103300.000 KRW.

What is stock market cap today?

The market cap of stock today is 1312177547000.000.

What is PEG ratio in 2024?

The current 0.009 is 0.009 in 2024.

What is the number of employees in 2024?

In 2024 the company has 2291.